Clinical Trials Using CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Clinical trials are research studies that involve people. The clinical trials on this list are studying CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Memory-Enriched T Cells in Treating Patients with Recurrent or Refractory Grade III-IV Glioma

    This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back or does not respond to treatment. Memory enriched T cells such as CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells may enter and express its genes in immune cells. Immune cells can be engineered to kill glioma cells in the laboratory by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells that allows them to recognize glioma cells. A vector called lentivirus is used to carry the piece of DNA into the immune cell. It is not known whether these immune cells will kill glioma tumor cells when given to patients.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Cellular Immunotherapy in Treating Patients with High-Risk Acute Lymphoblastic Leukemia

    This phase I trial studies the side effects and best dose of cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California